Revenue segments as reported by the company.

Consumer Health

Pharmaceutical

Medical Devices

Innovative Medicine

MedTech

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, marketing and administrative expenses

Research and development expense

In-process research and development

Interest expense

Other expense

Restructuring

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Johnson & Johnson

Band-Aid is a brand name of American pharmaceutical and medical devices giant Johnson & Johnson's line of adhesive bandages.

Band-Aid

Johnson's Baby is an American brand of baby cosmetics and skin care products owned by Johnson & Johnson. The brand dates back to 1893 when Johnson's Baby Powder was introduced. Product line consists of baby powder, shampoos, body lotions, massage oil, shower gels and baby wipes. The brand has reputation for making baby products that are "exceptionally pure and safe" since at least the 1980s.

Johnson's Baby

Aveeno is a brand of skin care and hair care products in the United States owned by American consumer goods and pharmaceutical company Johnson & Johnson. Aveeno was founded in 1945, and its first product was their Soothing Bath Treatment. The active ingredient in all Aveeno products are colloidal oats and/or oat extracts - Avenanthramides, which have been branded as "active naturals". Aveeno offers products to treat skin conditions such as eczema, psoriasis, urushiol-induced contact dermatitis, pruritus ani, chickenpox, hives, and sunburn.

Aveeno

Neutrogena is an American brand of skin care, hair care and cosmetics, that is headquartered in Los Angeles, California. According to product advertising at their website, Neutrogena products are distributed in more than 70 countries. Neutrogena was founded in 1930 by Emanuel Stolaroff, and was originally a cosmetics company named Natone. It is now part of the US-based Johnson & Johnson conglomerate, which bought the independent company in 1994.

Neutrogena

Clean & Clear is a line of dermatology products owned by Johnson & Johnson.

Clean & Clear

Listerine is a brand of antiseptic mouthwash product. It is promoted with the slogan "Kills germs that cause bad breath". Named after Joseph Lister, a pioneer of antiseptic surgery, Listerine was developed in 1879 by Joseph Lawrence, a chemist in St. Louis, Missouri.

Listerine

Acuvue (from "Accurate view") is a brand of disposable contact lenses made by Jacksonville-based Vistakon, a subsidiary of Johnson & Johnson (J&J).

Acuvue

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension. The MedTech segment includes a portfolio of products used in the interventional solutions, orthopaedics, surgery, and vision categories. The company was founded by Robert Wood Johnson I, James Wood Johnson, and Edward Mead Johnson Sr. in 1887 and is headquartered in New Brunswick, NJ.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Johnson & Johnson reports solid Q4 earnings, eyes $60B Pharma revenue

Johnson & Johnson's Q4 2022 showed steady operational growth and strong financial performance. The company aims for continued growth in Pharmaceuticals, focusing on key products and pipeline advancements. Challenges include managing costs, addressing sales declines, and navigating market uncertainties.

Johnson & Johnson reports resilient Q1 performance amidst challenges

Johnson & Johnson's Q1 2023 performance reflects resilience and growth across key segments despite short-term challenges.
The company's strategic focus on innovation, resource management, and portfolio diversification positions it for future success.
While facing legal and financial headwinds, Johnson & Johnson remains optimistic about its outlook for 2023 and beyond.
Increased guidance, product developments, and commitment to safety and innovation underscore the company's long-term growth potential.

Johnson & Johnson reports strong Q2 earnings and strategic growth plans

Johnson & Johnson showcased robust financial results in Q2, raising full-year guidance and highlighting growth in MedTech and Pharmaceuticals. Despite challenges from pricing pressures and litigation, the company remains focused on strategic opportunities and maintaining a strong market position. With a clear focus on innovation and growth, Johnson & Johnson is poised for continued success in the healthcare sector.

Johnson & Johnson posts strong Q3 results amidst growth strategies

Johnson & Johnson (JNJ) delivered robust Q3 results, showcasing growth in sales, earnings, and operational efficiency across key segments, positioning the company for future success.
While facing challenges from geopolitical factors, legal issues, and upcoming competition, JNJ's strategic strengths in acquisitions, innovation, and market presence offer avenues for sustained growth.
With a focus on key brands, pipeline advancements, and MedTech innovations, JNJ remains poised to meet revenue targets, navigate challenges, and capitalize on market opportunities in the coming years.

Johnson & Johnson reports robust 2023 performance and strategic growth outlook

Johnson & Johnson's strong 2023 performance in Innovative Medicine and MedTech drove operational sales growth. Despite inflationary pressures impacting margins, JNJ remains focused on enhancing shareholder returns and pursuing strategic M&A deals. Opportunities for growth in 2024 include new product launches and advancements in key focus areas.

Johnson & Johnson posts strong Q1 earnings, eyes growth opportunities

Johnson & Johnson's Q1 2024 earnings reflect solid performance across key segments, with a focus on innovation and strategic growth initiatives.
Despite challenges in certain segments, the company's proactive approach to restructuring and market dynamics positions it for future success.
Opportunities in Vision Care, Pulmonary Hypertension, and Orthopaedics underscore potential for sustained growth and market leadership.
Overall, Johnson & Johnson's diversified product portfolio and financial outlook support confidence in achieving growth targets for 2024.

Johnson & Johnson posts strong Q2 results, eyes growth opportunities

Johnson & Johnson delivered a robust performance in Q2 2024, driven by strong sales growth in both Innovative Medicine and MedTech segments, supported by strategic initiatives.
While facing challenges in certain markets and the need for continued innovation, the company's outlook remains positive with a solid guidance for the full year 2024.
By capitalizing on opportunities in key products and markets, Johnson & Johnson is well-positioned to navigate challenges and drive sustainable growth in the healthcare sector.

Johnson & Johnson reports robust Q3 earnings amidst legal challenges

Johnson & Johnson's Q3 2024 earnings call showcased strong financial performance, driven by growth in key segments and successful product launches. Despite facing challenges with talc litigation, the company remains focused on innovation, capital allocation, and resolving legal issues.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Apple

Amazon

Blackrock Inc

iShares Core S&P 500 ETF

Microsoft

ProShares Short S&P500

SPDR S&P 500 ETF Trust

ProShares Ultra S&P 500

UnitedHealth Group

Vanguard S&P 500 ETF

A fund that invests in the companies in the S&P 500 can be a great way to start a portfolio and invest for the long term.

Investing in S&P 500 ETFs

The U.S. Food and Drug Administration (FDA) has approved Johnson & Johnson's therapy for treating a type of multiple myeloma, the company said on Tuesday, giving another treatment option to patients with the incurable blood cancer.

Johnson & Johnson's blood cancer therapy gets U.S. FDA approval

Amgen

AstraZeneca

IQVIA Hlds

Novartis

Regeneron Pharmaceuticals

Biosimilars are bringing down prescription drug costs without sacrificing quality.

Biosimilars Are Revolutionizing Healthcare: Is This Industry Leader a Buy?

American Express

Bank of America

Goldman Sachs

Lockheed Martin

Netflix

Procter & Gamble

Schlumberger

AT&T

Tractor Supply

Tesla

Big Tech firms like Alphabet, Microsoft and Apple, as well as retail giants like Coca-Cola, are all set to report earnings this week.

Jim Cramer says these 13 companies' earnings helped drive markets higher

Dollar General

Moderna

Vertex Pharmaceuticals

Walmart

Recession-proof stocks must offer something that makes investors want to buy them even when the economy is tanking.

Which Stocks Are Most Likely to Thrive in a Recession? Here's What History Shows

Johnson & Johnson JNJ, -0.02% said surgical procedure volumes are returning to pre-pandemic levels in many parts of the world, a trend that cheered Wall Street and could bode well for other medical-technology heavyweights like Stryker Corp. SYK, -1.45% and Zimmer Biomet Holdings Inc. ZBH, -1.48%.

Patients are getting surgeries again, says J&J

Earnings season is upon us as companies announce financial results for the third quarter of 2022. The high inflation and rising interest rate environment has caused consumer sentiment to slow down, and many companies are missing earnings estimates.

2 Recession-Proof Stocks That Have Recently Beaten Earnings

The 2022 bear market might end up seeing 8 or 9 bear market rallies, with a lot more volatility to come. Ultra-low volatility defensive dividend aristocrats like JNJ are a great way to ride out even the most extreme market storms.

3 Reasons To Love Johnson & Johnson, But Buy These 2 Better Dividend Aristocrat Bargains

PepsiCo

"Nobody's championing what actually works: these old-line consumer packaged goods names that we all know," Cramer said.

Jim Cramer makes the bull case for consumer goods stocks

Johnson & Johnson (JNJ) continued with its long streak of earnings beat. It outpaced revenue estimates and raised its full-year revenue guidance.

JNJ Beats on Q3 Earnings: ETFs in Focus

JNJ stock is seen as a defensive play which has typically done well in bear markets. But there is one issue that makes longer-term forecasts uncertain

Does J&J Have Enough Alpha to Be a Solid Low Beta Stock?

Johnson & Johnson (NYSE: JNJ) reported market-beating results for its fiscal third quarter on Tuesday. Shares are still in the red as investors wanted more in terms of future guidance.

J&J reports a strong Q3 despite fears of recession: what went right?

J&J's enviable growth and focus on a consumer split means it is moving more slowly when it comes to mergers and acquisitions.

Johnson & Johnson Isn't Rushing into M&A

J&J (JNJ) beats estimates for third-quarter earnings as well as sales. It lowers the full-year sales guidance.

J&J (JNJ) Beats on Q3 Earnings, Cuts 2022 Sales View on Fx Woes

J&J CFO Joseph Wolk said the U.S. health care conglomerate is looking at "right sizing" itself, particularly as it moves from being a three-segment business to a two-segment business

Johnson & Johnson looks at job cuts despite weathering inflation impact

Johnson & Johnson (NYSE:JNJ ) Q3 2022 Earnings Conference Call October 18, 2022 8:30 AM ET Company Participants Jessica Moore - Vice President, Investor Relations Joe Wolk - Executive Vice President, Chief Financial Officer Thibaut Mongon - Executive Vice President & Worldwide Chairman, Consumer Health Ashley McEvoy - Executive Vice President, Worldwide Chairman, MedTech Jennifer Taubert - Executive Vice President, Worldwide Chairman, Pharmaceuticals Conference Call Participants Chris Schott - JPMorgan Larry Biegelsen - Wells Fargo Louise Chen - Cantor Fitzgerald Joshua Jennings - Cowen Joanne Wuensch - Citi Geoff Meacham - Bank of America Terence Flynn - Morgan Stanley Operator Good morning and welcome to Johnson & Johnson's Third Quarter 2022 Earnings Conference Call. All participants will be in a listen-only mode until the question-and-answer session of the conference.

Johnson & Johnson (JNJ) Q3 2022 Earnings Call Transcript

Johnson & Johnson  (NYSE:JNJ ) took to the earnings confessional earlier to report a third-quarter earnings and revenue beat, thanks to growing pharmaceutical sales.

Blue-Chip Pharma Stock Inches Higher After Q3 Win

The market rally looked poised to continue Tuesday.

J&J Leads Dow Jones Higher, but This Stock's an Even Bigger Winner

A rebound in the medical device business is among the reasons for the company's strong earnings.

Johnson & Johnson Earnings Top Estimates. Its CFO Explains What Went Right.

Johnson & Johnson topped third-quarter expectations on Thursday despite exchange-rate challenges, and JNJ stock advanced. The post Johnson & Johnson Notches Quarterly Beat, Outplaying Exchange-Rate Headwinds appeared first on Investor's Business Daily.

Johnson & Johnson Notches Quarterly Beat, Outplaying Exchange-Rate Headwinds

The healthcare-products company lowered its full-year sales guidance on the continuing impact from the runup in the dollar relative to other currencies around the world.

Johnson & Johnson Posts Higher Quarterly Sales Despite Strong Dollar

The company tightened its full-year adjusted profit forecast range. Sales at its medical devices unit rose to $6.78 billion on demand for contact lenses and wound-closure products.

Johnson & Johnson beats sales estimates on pharma strength

Shares of Johnson & Johnson JNJ, +1.30% rose 2.3% toward a two-month high in premarket trading Tuesday, after the drug and consumer products company reported third-quarter profit and sales that beat expectations, with all of its business segments topping forecasts. Net income rose to $4.46 billion, or $1.68 a share, from $3.67 billion, or $1.37 a share, in the year-ago period.

Johnson & Johnson stock jumps toward 2-month high after profit, sales beat expectations

The company expects sales in 2022 of $93 billion to $93.5 billion, down from prior expectations of $93.3 billion to $94.3 billion.

News for Johnson & Johnson Stock (JNJ)